Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (30)

2024

  1. A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919

  2. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

  2. Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

    Scientific Reports, Vol. 13, Núm. 1

  4. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701

2022

  1. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

    Open Forum Infectious Diseases

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

    Life science alliance, Vol. 5, Núm. 4

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2019

  1. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  2. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438

2018

  1. Executive summary of the consensus document on osteoporosis in HIV-infected individuals

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 312-314

2017

  1. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 3, pp. 844-849

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy

    JAMA - Journal of the American Medical Association, Vol. 316, Núm. 2, pp. 171-181

2015

  1. Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humana

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 4, pp. 250-258